-
What to do if lung cancer is resistant to targeted drugs?
Time of Update: 2022-08-20
2. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-OsimertinibClick below to learn more about clinical trialsThe problem of drug resistance of lung cancer targeted drugsIn non-small cell lung cancer, the most common driver gene mutation is EGFR mutation.
-
TROPION-Lung02: The first-line treatment of metastatic NSCLC with a new ADC+immunotherapy shows initial results!
Time of Update: 2022-08-20
Based on good research results, the Phase III TROPION-Lung08 study is exploring the efficacy of Dato-DXd + pembrolizumab versus pembrolizumab for first-line treatment of patients with metastatic NSCLC with PD-L1 TPS ≥ 50% .
-
WCLC 2022｜Subsequent treatment exploration and drug resistance mechanism of ALK-positive NSCLC patients
Time of Update: 2022-08-20
Comprehensive efficacy and safety analysis of brigatinib following alectinib treatment progression¹>>>>Research BackgroundAlectinib is the standard treatment option for patients with ALK-positive NSCLC .
Comprehensive efficacy and safety analysis of brigatinib following alectinib treatment progression¹>>>>Research BackgroundAlectinib is the standard treatment option for patients with ALK-positive NSCLC .
-
Mizuxing Xie Xie Zhu Jun and Guo Ye: Pola's Three Great Weapons (1) - MMAE Bystander Effect Laying a Mechanistic Basis for Breaking Through the Heterogeneity of DLBCL
Time of Update: 2022-08-20
Figure 5 GO29365 research results*BR: bendamustine combined with rituximab; PFS: progression-free survival; OS: overall survival; CR: complete responsePOLARIX study: Pola-R-CHP regimen is expected to improve the first-line cure rate of DLBCLThroughout the 25-year history of R-CHOP+X exploration, many new targeted drugs have failed miserably in the pursuit of higher cure rates .
-
Takeda's innovative drug brigatinib in the field of lung cancer treatment opens up a new pattern of treatment for ALK-positive advanced non-small cell lung cancer
Time of Update: 2022-08-20
Guidelines for the diagnosis and treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer in China [J].
Guidelines for the diagnosis and treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer in China [J].
-
Based in China, looking to the world｜Following the new progress of MM, exploring new ideas of diagnosis and treatment, CACA guideline tour and POST-EHA/ASCO MM special meeting was successfully held!
Time of Update: 2022-08-20
On August 7, 2022, the China Anti-Cancer Association Hematology and Tumor Diagnosis and Treatment Guidelines Tour and POST-EHA/ASCO MM sponsored by the China Anti-Cancer Association Hematology and Tumor Professional Committee, the Hematology Hospital of the Chinese Academy of Medical Sciences and the National Hematological Disease Clinical Medical Center The special meeting was successfully held .
-
2022 WCLC Hotspot - Research Progress of Locally Advanced NSCLC
Time of Update: 2022-08-20
*For medical professional reading reference onlyA first look at the cutting-edge research progress of the WCLC conference in 2022!About 1/3 of non-small cell lung cancer (NSCLC) patients are already in stage III at the time of initial diagnosis, but despite aggressive standard treatment, the clinical outcomes of patients with locally advanced NSCLC are still poor, with the 5-year total of stage III NSCLC.
-
Resection of acoustic neuroma by subperineuronal dissection
Time of Update: 2022-08-20
】 Research Background With the development of microneurosurgery technology, surgical equipment and intraoperative electrophysiological monitoring, complete resection of acoustic neuromas (VSs) and postoperative facial nerve function preservation have improved significantly, and hearing preservation has gradually become a surgical pursuit .
-
WCLC Voice of China The best solution for immunotherapy resistance.. The efficacy of immunotherapy after EGFR TKI treatment failure
Time of Update: 2022-08-20
At this year's WCLC conference, a study conducted by Professor Lu Shun's team from the Chest Hospital Affiliated to Shanghai Jiao Tong University explored the best options for patients with oligoprogression after resistance to immunotherapy .
-
Crizotinib-resistant crizotinib-resistance patients with MET-amplified brain metastases from lung cancer
Time of Update: 2022-08-20
case providerProfessor Zhang Weihong: In patients with MET-amplified NSCLC brain metastases after EGFR-TKI resistance, the efficacy of switching to sivotinib after crizotinib resistance is durableEGFR mutation is the most common type of mutation in Chinese non-small cell lung cancer (NSCLC) patients, present in about half of the patients .
-
WCLC 2022｜Can sintilimab combined with short-course chemotherapy regimens promote strengths and avoid weaknesses?
Time of Update: 2022-08-20
At this WCLC meeting, it was announced that sintilimab combined with two-cycle chemotherapy has Efficacy data in treatment-naïve advanced squamous non-small cell lung cancer (sq-NSCLC) .
At this WCLC meeting, it was announced that sintilimab combined with two-cycle chemotherapy has Efficacy data in treatment-naïve advanced squamous non-small cell lung cancer (sq-NSCLC) .
-
Clinical application guideline for the treatment of chronic prostatitis with Chinese patent medicines
Time of Update: 2022-08-20
Chinese patent medicine treatment of CP pain and discomfortIt is recommended to use Qianliexin capsule in combination with western medicine to treat CP patients with pain and discomfort as the main clinical manifestation, which can improve clinical symptoms such as tingling in the lower abdomen and surrounding areas (recommendation level 1B) .
-
【Science Sub-Journal】Study finds that circadian clock disturbance can directly accelerate the progression of colorectal cancer!
Time of Update: 2022-08-20
This article is original from Translational Medicine Network, please indicate the source for reprinting Author: SophiaIntroduction: An alarming increase in the incidence of colorectal cancer (CRC) in
-
Research progress of bacterial membrane nano-tumor vaccine
Time of Update: 2022-08-20
Schematic diagram of the technical route for the preparation of two nano-tumor vaccines based on bacterial membrane materials Source: National Nanoscience Center, Chinese Academy of SciencesRecently, the research team of Zhao Xiao, Zhao Ruifang and Nie Guangjun of the National Nanoscience Center of the Chinese Academy of Sciences has made important progress in bacterial membrane nano-tumor vaccine .
-
Express treatment of breast cancer, the first oral estrogen receptor degrader is expected to come out
Time of Update: 2022-08-20
▲If you have any business needs, please long press to scan the QR code above, or▎Edited by WuXi AppTec Content Team▲ Molecular formula of Elacestrant (Image source: Aethyta, Public domain, via Wikimedia Commons)WuXi AppTec provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical industry, covering chemical drug R&D and production, biological research, preclinical testing and clinical trial R&D, cell and gene therapy R&D, testing and production and other fields .
-
It's hammered!
Time of Update: 2022-08-20
Collectively, this study demonstrates that BRAF/MEK-targeted therapy is associated with increased AR expression in tumor cells, thereby promoting treatment resistance, and that AR blockade by anti-androgens such as enzalutamide may promote resistance in both male and female patients.
-
Amgen empties "BCMA pipeline", involving dual antibody, ADC
Time of Update: 2022-08-20
Amgen’s second-generation dual antibody technology platform: HLE-BiTE / Baiaoyun testRecently, one year after restarting the clinical practice, Amgen announced that it would abandon the development of its only BCMA drug, AMG701, for the reason given "for corporate strategic considerations" .
-
Breaking the Cocoon into a Butterfly: Condésai mRNA-edited DC Personalized Tumor Vaccine IND Officially Accepted
Time of Update: 2022-08-20
At the same time, in order to enhance the anti-tumor immunity of DC, the research team of Condessa developed the first therapeutic tumor vaccine in China that combines mRNA with DC .
-
Liu Qiang's group reveals the mechanism of PI3K/mTOR inhibitor reversing CDK4/6 inhibitor resistance in breast cancer
Time of Update: 2022-08-20
Recently, Liu Qiang's research group from Sun Yat-sen Memorial Hospital of Sun Yat-sen University published a research paper entitled "Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR Inhibitors" in Science China Life Sciences.
-
Targeting ZNF117 induces differentiation of GBM stem cells into oligodendrocyte lineage
Time of Update: 2022-08-20
Jun Liu of Yale University Neurosurgery and colleagues combined genome-wide image-based RNAi screening with single-cell sequencing (scRNA-seq) to detect zinc finger protein 117 (ZNF117, or H-PLK) as a regulator of GSCs differentiation .
